Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RIVAL-02
- Development stage
- Preclinical
- Lead developer
- Turnstone Biologics
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Peptides, Nanoparticles → Drug Delivery Systems
01
Overview
**RIVAL-02** is a Turnstone Biologics preclinical oncology program directed at **human papillomavirus antigens** in HPV-positive tumors. Turnstone's pipeline described complementary therapeutic approaches including an engineered oncolytic vaccinia virus platform, peptide nanoparticle approaches, and rhabdovirus-based approaches. The intended mechanism is to generate HPV antigen-directed antitumor immune responses while oncolytic viral modalities may also promote tumor-cell lysis and immunogenic remodeling of the tumor microenvironment.
- Other names
- RIVAL-2RIVAL2RIVAL 2
02
Targets
HPV16 E7 (Human papillomavirus 16 E7 protein)
Beyond the preview
Go deeper on RIVAL-02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RIVAL-02.